Lipoprotein(a) - treatments in development

Expert Opin Pharmacother. 2025 Dec 6. doi: 10.1080/14656566.2025.2601062. Online ahead of print.ABSTRACTINTRODUCTION: Lipoprotein(a) [Lp(a)] is established as an independent risk factor for atheromatous cardiovascular disease and aortic valve stenosis. Currently available lipid-lowering pharmacother

B Brian Tomlinson

Tirzepatide vs. Semaglutide: clinical decision-making in the GLP-1 landscape

Expert Opin Pharmacother. 2025 Dec 6. doi: 10.1080/14656566.2025.2601060. Online ahead of print.ABSTRACTBACKGROUND: Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established, e

A Alvin Mondoh

Methodological Appraisal of Ongoing Trial of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Younger Patients: From Incentives to Guideline-Informing Evidence

Eur J Cardiothorac Surg. 2025 Dec 1;67(12):ezaf348. doi: 10.1093/ejcts/ezaf348.ABSTRACTOBJECTIVES: To critically appraise the design of the ongoing multicentre, randomized START YOUNG trial comparing transcatheter aortic valve implantation (TAVI) with bioprosthetic surgical aortic valve replacement

M Milan Milojevic

UV-cure hydrogels for cardiac regeneration: a comprehensive review

Stem Cell Res Ther. 2025 Dec 5. doi: 10.1186/s13287-025-04845-x. Online ahead of print.ABSTRACTCardiovascular diseases (CVDs), particularly myocardial infarction (MI), cause irreversible cardiomyocyte loss and scar formation, severely compromising cardiac function. Despite advances in cardiovascular

H Hossein Rayat Pisheh